Ornithine-Transcarbamylase Deficiency - Pipeline Review, H2 2017; New Report Launched

DrugPipeline.net has announced the addition of “Ornithine-Transcarbamylase Deficiency - Pipeline Review, H2 2017” research report to their website www.DrugPipeline.net


Bangalore, India -- (SBWIRE) -- 04/16/2018 -- Ornithine-Transcarbamylase Deficiency - Pipeline Review, H2 2017, provides an overview of the Ornithine-Transcarbamylase Deficiency (Genetic Disorders) pipeline landscape.

Ornithine transcarbamylase (OTC) deficiency is a rare X-linked genetic disorder characterized by complete or partial lack of the enzyme ornithine transcarbamylase (OTC). OTC plays an important role in the break down and removal of nitrogen the body (urea cycle). The lack of the OTC enzyme results in excessive accumulation of nitrogen, in the form of ammonia (hyperammonemia), in the blood. Symptoms include vomiting, refusal to eat, progressive lethargy, and coma. Treatment includes nitrogen scavenging agents.

Report Highlights
Ornithine-Transcarbamylase Deficiency - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Ornithine-Transcarbamylase Deficiency (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ornithine-Transcarbamylase Deficiency (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Ornithine-Transcarbamylase Deficiency and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II and Preclinical stages are 1, 1, 1 and 6 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Ornithine-Transcarbamylase Deficiency (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

- The pipeline guide provides a snapshot of the global therapeutic landscape of Ornithine-Transcarbamylase Deficiency (Genetic Disorders).
- The pipeline guide reviews pipeline therapeutics for Ornithine-Transcarbamylase Deficiency (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ornithine-Transcarbamylase Deficiency (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Ornithine-Transcarbamylase Deficiency (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Ornithine-Transcarbamylase Deficiency (Genetic Disorders)

Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Ornithine-Transcarbamylase Deficiency (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Ornithine-Transcarbamylase Deficiency (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Spanning over 42 pages "Ornithine-Transcarbamylase Deficiency - Pipeline Review, H2 2017" report covers Introduction, Report Coverage, Ornithine-Transcarbamylase Deficiency - Overview, Ornithine-Transcarbamylase Deficiency - Therapeutics Development, Ornithine-Transcarbamylase Deficiency - Therapeutics Assessment, Ornithine-Transcarbamylase Deficiency - Companies Involved in Therapeutics Development, Ornithine-Transcarbamylase Deficiency - Drug Profiles, Ornithine-Transcarbamylase Deficiency - Dormant Projects, Appendix. This report Covered Companies - Arcturus Therapeutics Inc (Inactive), Lucane Pharma SA, PhaseRx Inc, Promethera Biosciences SA, Selecta Biosciences Inc, Translate Bio Inc, Ultragenyx Pharmaceutical Inc, Unicyte AG.

For more information Visit at: https://www.drugpipeline.net/global-markets-direct/ornithine-transcarbamylase-deficiency-pipeline-review-h2-2017

Find all Pharma and Healthcare Reports at - http://www.drugpipeline.net/catalog/pharma-healthcare

Related Reports;

Neurofibromatoses Type I (Von Recklinghausen's Disease) - Pipeline Review, H2 2017 - Visit at - https://www.drugpipeline.net/global-markets-direct/neurofibromatoses-type-i-von-recklinghausen%E2%80%99s-disease-pipeline-review-h2-2017

Usher Syndrome - Pipeline Review, H2 2017 - Visit at - https://www.drugpipeline.net/global-markets-direct/usher-syndrome-pipeline-review-h2-2017

About DrugPipeline.net
DrugPipeline.net is a market research reports distribution platform which hosts research reports from all leading global market research firms related to pharma industry. It also assist decision makers locate the right market research solution from a single place.